Author Archives: admin

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01755-4/fulltext

Posted in Uncategorized | Comments Off on 1-year outcomes in hospital survivors with COVID-19

Abstract Fluvoxamine, an SSRI and sigma-1 receptor agonist, has so far shown promise in the prevention of COVID-19 progression as an early treatment option in 3 conducted trials. The aim of this study was to evaluate the safety and efficacy … Continue reading

Posted in Uncategorized | Comments Off on Safety and efficacy of fluvoxamine in COVID-19 ICU patients

Abbreviated Highlights: In several previously published studies, the incidence of Acute Ischemic Stroke ranged from 0.9% to 2.7% in those with COVID-19, …  One of the studies calculated a more than sevenfold greater risk of Acute Ischemic Stroke among patients … Continue reading

Posted in Uncategorized | Comments Off on Covid-19 related stroke: No preventative value of antithrombotic therapy

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500775/

Posted in Uncategorized | Comments Off on Rapid response to selective serotonin reuptake inhibitors in post-COVID depression

Agha H, McCurdy CR. In vitro and in vivo sigma 1 receptor imaging studies in different disease states. RSC Med Chem. 2021 Oct 8;12(2):154-177. doi: 10.1039/d0md00186d. PMID: 34046607; PMCID: PMC8127618. https://pubmed.ncbi.nlm.nih.gov/34046607/

Posted in Uncategorized | Comments Off on In vitro and in vivo sigma 1 receptor imaging studies in different disease states

Alopecia areata (AA) is an autoimmune disorder that usually results in unpredictable, patchy hair loss. It is associated with multiple comorbidities and shares a similar inflammatory signature with dementia. The great negative psychosocial impact of AA may result in poor … Continue reading

Posted in Uncategorized | Comments Off on Association of Alopecia Areata with increased Risk of Dementia

Abstract:  “The Sigma-1 receptor (S1R) is an endoplasmic reticulum (ER) chaperone protein that has been implicated in attenuating inflammatory stress-mediated brain injuries. Selective S1R agonists represent a new class of therapeutic agent for treating neuropsychiatric and neurodegenerative disorders, however, to … Continue reading

Posted in Uncategorized | Comments Off on Brain-derived neurotrophic factor for high-throughput evaluation of selective Sigma-1 receptor ligands

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext

Posted in Uncategorized | Comments Off on Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19

Shi M, Chen F, Chen Z, Yang W, Yue S, Zhang J, Chen X. Sigma-1 Receptor: A Potential Therapeutic Target for Traumatic Brain Injury. Front Cell Neurosci. 2021 Sep 30;15:685201. doi: 10.3389/fncel.2021.685201. PMID: 34658788; PMCID: PMC8515188. https://pubmed.ncbi.nlm.nih.gov/34658788/

Posted in Uncategorized | Comments Off on Sigma-1 Receptor: A Potential Therapeutic Target for Traumatic Brain Injury

“In conclusion, at present it is unclear whether a Sig-1R agonist or Sig-1R antagonist would be better for inhibiting SARS-CoV-2 replication. Experiments comparing these ligands in the same assay are warranted. Until then, classifying anti- inflammatory anaesthesia drugs such as … Continue reading

Posted in Uncategorized | Comments Off on Anesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair